Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

MORPHEUS Prognosis Improvement of Unprovoked Venous Thromboembolism Using Personalized Anticoagulant Therapy

Coordinator
Centre Hospitalier Regional Et Universitaire De Brest, France
Runs
1 December 2023 to 30 November 2028
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
20 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101095698

What the project is doing

In the project's own words, from its summary on CORDIS.

Venous thromboembolism (VTE) is a frequent and life-threatening disease. In 50% of cases, VTE occurs in the absence of any major risk factors (unprovoked VTE). In these patients, when anticoagulation is stopped after 3 months of anticoagulation, more than 35% will develop recurrent VTE. Consequently, international guidelines recommend to treat these patients “indefinitely”. However, such practice exposes them to a substantial increase risk of bleeding.

Nevertheless, after several years of anticoagulation in all patients with unprovoked VTE, the risk of anticoagulant-related bleeding is expected to exceed the risk of recurrent VTE after stopping treatment. In addition, extending anticoagulation indefinitely in all patients with unprovoked VTE exposes 65% of patients to an unjustified high risk of bleeding, who would never have experienced recurrent VTE after stopping treatment.

In this setting, optimal duration and management of anticoagulation remains a pivotal and unresolved challenging issue which has the potential to markedly improve long-term prognosis of unprovoked VTE. Based on quantitative and qualitative approaches, MORPHEUS will for the first time integrate (i) clinical, laboratory and imaging biomarkers (personalized medicine) and (ii) socio-anthropological markers (patient-centred model) into sets of prediction rules for optimizing anticoagulant management integrated in a shared decision-making process.

The ultimate goal of the European “MORPHEUS” project will be to develop and validate a time-dependent multi-component tool integrated in a shared decision-making process regarding anticoagulant treatment duration in patients with unprovoked VTE. The whole MORPHEUS program, leaded by a consortium of outstanding European researchers in the field of VTE, will constitute a major breakthrough compared with the present standard of care in patients with unprovoked VTE with major scientific, public health, economic, and societal impacts.

Topics

Who is involved

OrganisationCityCountryRole
Centre Hospitalier Regional Et Universitaire De BrestBrestFranceCoordinator
Universite De GeneveGeneveSwitzerlandAssociatedpartner
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Region SyddanmarkVejleDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Fundacion Instituto De Investigacion Marques De ValdecillaSantanderSpainThird party
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y CajalMadridSpainThird party
Servicio Madrileno De SaludMadridSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De BordeauxBordeauxFranceParticipant
Universite De BrestBrestFranceThird party
Universite Paris CiteParisFranceParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Todaytomorrow B.v.RotterdamNetherlandsParticipant
Uniwersytet Medyczny Im Piastow Slaskich We WroclawiuWroclawPolandThird party
Warszawski Uniwersytet MedycznyWarszawaPolandParticipant
Kungliga Tekniska HoegskolanStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI